Skip to main content
Top
Published in: Indian Journal of Hematology and Blood Transfusion 1/2014

01-09-2014 | Case Report

Symptomatic Acquired Haemophilia Due to Circulating Antibodies Against Both Factor VIII and IX in a Non-haemophiliac Patient

Authors: Sharat Damodar, Prashantha Bhat, Sitalakshmi Balasubramaniam

Published in: Indian Journal of Hematology and Blood Transfusion | Special Issue 1/2014

Login to get access

Abstracts

Acquired haemophilia is a very rare condition, occurring in less than 2 per million populations. This condition is caused commonly by acquired antibodies against factor VIII and rarely by antibodies against factor IX. Here we describe an extremely rare presentation of idiopathic acquired haemophilia in an otherwise healthy male patient, caused by simultaneous occurrence of circulating antibodies against both factor VIII and IX.
Literature
1.
go back to reference Green D, Lechner K (1981) A survey of 215 non-hemophilic patients with inhibitors to factor VIII. Thromb Haemost 45:200–203PubMed Green D, Lechner K (1981) A survey of 215 non-hemophilic patients with inhibitors to factor VIII. Thromb Haemost 45:200–203PubMed
2.
go back to reference Jedidi I, Hdiji S, Ajmi N, Makni F, Masmoudi S et al (2011) Acquired haemophilia B: a case report and literature review. Ann Biol Clin (Paris) 69(6):685–688 Jedidi I, Hdiji S, Ajmi N, Makni F, Masmoudi S et al (2011) Acquired haemophilia B: a case report and literature review. Ann Biol Clin (Paris) 69(6):685–688
3.
go back to reference Morrison AE, Ludlam CA, Kessler C (1993) Use of porcine factor VIII in the treatment of patients with acquired hemophilia. Blood 81:1513–1520PubMed Morrison AE, Ludlam CA, Kessler C (1993) Use of porcine factor VIII in the treatment of patients with acquired hemophilia. Blood 81:1513–1520PubMed
4.
go back to reference Collins PW, Hirsch S, Baglin TP, Dolan G, Hanley J et al (2007) Acquired haemophilia A in the UK: a 2-year national surveillance study by UK Haemophilia Centre Doctors’ Organisation. Blood 109:1870–1877PubMedCrossRef Collins PW, Hirsch S, Baglin TP, Dolan G, Hanley J et al (2007) Acquired haemophilia A in the UK: a 2-year national surveillance study by UK Haemophilia Centre Doctors’ Organisation. Blood 109:1870–1877PubMedCrossRef
5.
go back to reference Reussi C, Altman R, Rouvier J, Maino R (1966) Combined factor VIII and IX inhibitors in a girl. Thromb Diath Haemorrh 16(3):549–558PubMed Reussi C, Altman R, Rouvier J, Maino R (1966) Combined factor VIII and IX inhibitors in a girl. Thromb Diath Haemorrh 16(3):549–558PubMed
6.
go back to reference Moake JI, Kent CJ, Meta LD, Wright LC (1976) Circulating IgG antibodies against Factors IX and VIII in multiple sclerosis. Acta Haematol 55:53PubMedCrossRef Moake JI, Kent CJ, Meta LD, Wright LC (1976) Circulating IgG antibodies against Factors IX and VIII in multiple sclerosis. Acta Haematol 55:53PubMedCrossRef
7.
go back to reference Gouyon JB, Seiller F, Deries X, Alison M, Lorenzini JL et al (1985) Inhibitors of factors VIII and IX in a child with Henoch-Schönlein syndrome. Am J Pediatr Hematol Oncol 7(4):376–377PubMed Gouyon JB, Seiller F, Deries X, Alison M, Lorenzini JL et al (1985) Inhibitors of factors VIII and IX in a child with Henoch-Schönlein syndrome. Am J Pediatr Hematol Oncol 7(4):376–377PubMed
8.
go back to reference Carmassi F, Giannarelli C, De Giorgi A, De Negri F (2007) Combined factor VIII and IX inhibitors in a non-haemophilic patient: successful treatment with immunosuppressive drugs. Haemophilia 13:106–107PubMedCrossRef Carmassi F, Giannarelli C, De Giorgi A, De Negri F (2007) Combined factor VIII and IX inhibitors in a non-haemophilic patient: successful treatment with immunosuppressive drugs. Haemophilia 13:106–107PubMedCrossRef
9.
go back to reference Campos-de-Magalhaes M, Brandao-Mello CE, Pires MLE, Salgado MCF, de Brito SB et al (2011) Factor VIII and IX deficiencies related to acquired inhibitors in a patient with chronic hepatitis C virus infection receiving treatment with pegylated interferon plus ribavirin. Hematology 16(2):80–85PubMedCrossRef Campos-de-Magalhaes M, Brandao-Mello CE, Pires MLE, Salgado MCF, de Brito SB et al (2011) Factor VIII and IX deficiencies related to acquired inhibitors in a patient with chronic hepatitis C virus infection receiving treatment with pegylated interferon plus ribavirin. Hematology 16(2):80–85PubMedCrossRef
10.
go back to reference Huth-Kuhne A, Baudo F, Collins P, Ingerslev J, Kessler C et al (2009) International recommendations on the diagnosis and treatment of patients with acquired haemophilia A. Haematologica 94:566–575PubMedCrossRefPubMedCentral Huth-Kuhne A, Baudo F, Collins P, Ingerslev J, Kessler C et al (2009) International recommendations on the diagnosis and treatment of patients with acquired haemophilia A. Haematologica 94:566–575PubMedCrossRefPubMedCentral
11.
go back to reference Delgado J, Jimenez-Yuste V, HernandezNavarro F, Villar A (2003) Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol 121(1):21–35PubMedCrossRef Delgado J, Jimenez-Yuste V, HernandezNavarro F, Villar A (2003) Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol 121(1):21–35PubMedCrossRef
Metadata
Title
Symptomatic Acquired Haemophilia Due to Circulating Antibodies Against Both Factor VIII and IX in a Non-haemophiliac Patient
Authors
Sharat Damodar
Prashantha Bhat
Sitalakshmi Balasubramaniam
Publication date
01-09-2014
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue Special Issue 1/2014
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-013-0270-3

Other articles of this Special Issue 1/2014

Indian Journal of Hematology and Blood Transfusion 1/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine